Providing progressive cancer treatment and compassionate care.

Cancer News – 2018

  • Tivozanib for Renal Cell Cancer

    The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC). About tivozanib Tivozanib is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. In the current clinical trial, 351 patients with advanced RCC were treated with either tivozanib or Nexavar (sorafenib) and directly compared.  The … Continue reading "Tivozanib for Renal Cell Cancer" […]

  • Keytruda Immunotherapy for Treatment of Liver Cancer

    According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib), (1) and has not been approved by the US for use in patients with liver cancer. Keytruda was approved as a … Continue reading "Keytruda Immunotherapy for Treatment of Liver Cancer" […]

  • U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma

    The U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.1 About Empliciti Empliciti is an immunostimulatory antibody that specifically targets Signaling … Continue reading "U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma" […]

  • Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC

    The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori (crizotinib) and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on Alcensa (alectinib) or Zykadia … Continue reading "Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC" […]

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib … Continue reading "FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC" […]

  • 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer

    Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT) may be beneficial for patients with breast cancer and more than 9 involved axially lymph nodes (ALN), according to a study presented at the 2018 ESMO Congress in Munich, Germany.1 Though conventional chemotherapy is preferred over HDCT in most patients with high-risk early breast cancer … Continue reading "20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer" […]

  • New Treatment Approved for Influenza

    The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients aged ≥12 years old who have been symptomatic for no more than 48 hours. Xofluza is a first-in-class, single-dose oral medicine with a novel mechanism of action designed to target influenza A and B viruses, … Continue reading "New Treatment Approved for Influenza" […]

  • November Is National Lung Cancer Awareness Month

    Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the advancement of precision cancer medicines and immunotherapy. Lung cancer however remains the second … Continue reading "November Is National Lung Cancer Awareness Month" […]

  • Laurie MacCaskill Partners with CancerConnect

    KETCHUM – LOS ANGELES: Laurie MacCaskill, a 12-year survivor of pancreatic cancer and former chair of the Pancreatic Cancer Action Network has announced a newly established partnership with Cancer Connect to support pancreatic cancer patients with information, support and inspiration. Cancer Connect, a national organization provides support and information to more than 1 million patients … Continue reading "Laurie MacCaskill Partners with CancerConnect" […]

  • Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone

    Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable mutations in non-small cell lung cancer (NSCLC), researchers from the Abramson Cancer Center of … Continue reading "Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone" […]